Maraviroc Patients May Need Periodic Tropism Testing With Monogram Assay, FDA Panel Says | GenomeWeb
The possibility that patients may stop responding to Pfizer’s investigational HIV drug maraviroc due to resistance or co-receptor switching may require them to be periodically tested with Monogram’s Trofile assay, a US Food and Drug Administration advisory panel said last week.
The Antiviral Drugs Advisory Committee’s unanimous recommendation April 24, which also urged the accelerated approval of maraviroc, raises concerns that the additional cost of periodic testing may discourage patients from using the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.